about
The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.A new microarray substrate for ultra-sensitive genotyping of KRAS and BRAF gene variants in colorectal cancer.Phenotypic and molecular differences between giant-cell tumour of soft tissue and its bone counterpart.Is laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in Europe.Integrity and Quantity of Total Cell-Free DNA in the Diagnosis of Thyroid Cancer: Correlation with Cytological ClassificationMutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.Implementation of a companion diagnostic in the clinical laboratory: the BRAF example in melanoma.Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone.Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.BRAFV600E detection in melanoma is highly improved by COLD-PCR.A high-resolution melting protocol for rapid and accurate differential diagnosis of thyroid nodules.Personalized laboratory medicine: a patient-centered future approachSchwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutationIs laboratory medicine ready for the era of personalized medicine? A survey addressed to laboratory directors of hospitals/academic schools of medicine in EuropeAssociation between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancerGenetic and epigenetic factors in regulation of microRNA in colorectal cancersApplication of COLD-PCR for improved detection of NF2 mosaic mutationsAnalytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNARNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy
P50
Q34084873-9B5F4D0E-DBF3-4999-952D-560CF407B0CAQ34639858-6A14653B-5F0D-4CC0-BA16-37209EECB4ADQ36364836-36DFE9FA-DEFC-4DE6-B4CF-072BEFA8ED0DQ40877276-9DED34F4-B40F-4B4B-A033-D142E0382E2CQ41181289-29F4322A-26DB-45DA-98BB-34DD2FE43AFAQ41225190-190226BB-1032-48F8-AC57-296823DE82FDQ41749375-BC0D57A5-8DAA-450E-8181-D25EFBA369A1Q47815298-AA420D5D-EF03-4245-B632-56278DB64699Q50939159-2766E230-80E4-4B21-B9B9-9B00DA20D52BQ54391292-4EAED3E2-4DA4-4D1F-83E0-2852CB73BEFCQ54501897-8EAC54F7-6CE1-4339-BAA1-1249FC780C86Q57176546-9F282A20-2E4E-4CDF-960B-21403EA8D3B9Q57737866-8A3CBDC5-1077-4791-B9A0-066FE5718A7CQ57994285-0368DE97-58B1-42DA-943E-198E4A856930Q60547875-91BD437A-6AF4-4A65-A4BC-A1E043744104Q84990760-8DA3E2F8-B01A-4D69-BC61-73AE45676560Q87848049-3C92E965-F889-48BF-BBD0-9030E2923400Q90231820-C2BD5BE7-02B0-4928-A461-B3D65A8FA088Q93024273-B6E1AAE8-779E-4656-8E7B-51DBE811EBE1
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Irene Mancini
@ast
Irene Mancini
@en
Irene Mancini
@es
Irene Mancini
@nl
type
label
Irene Mancini
@ast
Irene Mancini
@en
Irene Mancini
@es
Irene Mancini
@nl
prefLabel
Irene Mancini
@ast
Irene Mancini
@en
Irene Mancini
@es
Irene Mancini
@nl
P106
P1153
23100369000
P21
P31
P496
0000-0002-7814-6435